Latest News and Press Releases
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
December 08, 2024 12:40 ET
|
Agios Pharmaceuticals, Inc.
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate...
TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
December 08, 2024 12:35 ET
|
Janssen Cilag International NV
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy1,2 BEERSE, BELGIUM, Dec. ...
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
December 08, 2024 12:30 ET
|
Novartis Pharma AG
Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key...
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
December 08, 2024 12:30 ET
|
F. Hoffmann-La Roche Ltd
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse...
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
December 08, 2024 12:30 ET
|
C4 Therapeutics, Inc.
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR);...
業界領先的律師事務所 ROSEN 鼓勵 Symbotic Inc. 投資者在該公司首次提出對 SYM 證券集體訴訟的重要截止日期前聘請律師
December 08, 2024 12:11 ET
|
The Rosen Law Firm PA
紐約, Dec. 09, 2024 (GLOBE NEWSWIRE) -- 事因:全球投資者權益律師事務所 Rosen Law Firm 宣佈代表曾於 2024 年 2 月 8 日至 2024 年 11 月 26 日期間(包括首尾兩日,簡稱「集體訴訟期」)購買 Symbotic Inc. (NASDAQ: SYM) 證券的人士提出集體訴訟。 集體訴訟經已提出。...
ROSEN, A LEADING LAW FIRM, Encourages Symbotic Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SYM
December 08, 2024 12:11 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Symbotic...
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
December 08, 2024 12:00 ET
|
Affimed N.V.
The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of...
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
December 08, 2024 12:00 ET
|
Molecular Partners
MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 08, 2024 12:00 ET
|
Cogent Biosciences, Inc.
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with...
- December 08, 2024 02:32 ET EliteSignals Unveils Revolutionary Forex Trading Bot: EliteX
- December 07, 2024 17:39 ET Caribbean Airlines Brings the Region Closer with New Service to Guadeloupe